BRPI0412255A - tratamento da disfunção sexual masculina - Google Patents

tratamento da disfunção sexual masculina

Info

Publication number
BRPI0412255A
BRPI0412255A BRPI0412255-0A BRPI0412255A BRPI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
male sexual
ejaculation
relates
Prior art date
Application number
BRPI0412255-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Peter Wayman
Rachel Jane Russell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0412255A publication Critical patent/BRPI0412255A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
BRPI0412255-0A 2003-07-23 2004-07-12 tratamento da disfunção sexual masculina BRPI0412255A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction
PCT/IB2004/002300 WO2005006899A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0412255A true BRPI0412255A (pt) 2006-09-19

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412255-0A BRPI0412255A (pt) 2003-07-23 2004-07-12 tratamento da disfunção sexual masculina

Country Status (12)

Country Link
EP (1) EP1656183B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528171A (cg-RX-API-DMAC7.html)
AT (1) ATE380048T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412255A (cg-RX-API-DMAC7.html)
CA (1) CA2533177A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001702A1 (cg-RX-API-DMAC7.html)
GB (1) GB0317227D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05014200A (cg-RX-API-DMAC7.html)
TW (1) TW200510424A (cg-RX-API-DMAC7.html)
UA (1) UA79674C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005006899A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505957B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361B (zh) * 2023-09-28 2026-08-07 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CL2004001702A1 (es) 2005-05-13
CA2533177A1 (en) 2005-01-27
UA79674C2 (en) 2007-07-10
EP1656183A1 (en) 2006-05-17
ATE380048T1 (de) 2007-12-15
WO2005006899A1 (en) 2005-01-27
MXPA05014200A (es) 2006-07-03
TW200510424A (en) 2005-03-16
ZA200505957B (en) 2006-11-29
GB0317227D0 (en) 2003-08-27
JP2006528171A (ja) 2006-12-14
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
EA200702619A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
BRPI0414592A (pt) antagonistas de receptores de trombina
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
SE0202241D0 (sv) Novel Compounds
TNSN07196A1 (en) Potentiators of glutamate receptors
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
NO20071272L (no) Modulatorer av muskarine reseptorer.
NO20070248L (no) Fremgangsmater for fremstilling av gonadotropinfrigjorende hormon reseptor antagonister
EA200970051A1 (ru) Антагонист рецептора il-8
PT1636221E (pt) Compostos de 3-heterociclil-azetidina úteis como antagonistas dos receptores nk1/nk2
TW200420543A (en) Treatment of female sexual dysfunction
NO20073369L (no) Modulatorer av muskarinreseptorer
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
WO2002100350A3 (en) Dopamine receptor ligands and therapeutic methods based thereon
TW200510424A (en) Treatment of male sexual dysfunction
WO2007014263A3 (en) Octahydroisoquinoline compounds as opioid receptor modulators

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.